Answers are grounded in this paper and cite their sources.
Cisplatin-etoposide and carboplatin-paclitaxel regimens were associated with comparable efficacy when used with concurrent definitive radiotherapy for patients with stage III unresectable NSCLC. The toxic effect profiles favored the carboplatin-paclitaxel regimen.
No takes yet. Share an insight, caveat, or question.
Steuer et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: